Irina Surovtsova

Dr. Irina Surovtsova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
ATAndreas Teufel
Andreas Teufel
IRIsaac Rodriguez
Isaac Rodriguez
CWClaudia Winzler
Claudia Winzler
DKDaria Kokh
Daria Kokh
MEMatthias Ebert
Matthias Ebert
PMPhilipp Morakis
Philipp Morakis
Background and Aims: Primary liver cancer (PLC) ranks among of the most common cancers worldwide. Within this group, a minority of cases displays characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), known as combined hepatocellular cholangiocarcinoma (cHCC- CCA). Currently, there is no specific standardized therapy for these mixed tumors. Therefore, the aim of our study was to analyze the clinical course, treatment and outcome of cHCC-CCA patients in a European population-based registry. Methods: We investigated 9,144 patients with PLC (6,622 HCC, 2,356 iCCA, and 166 cHCC-CCA) diagnosed between 2009 and 2020. All data were obtained from Clinical Cancer Registry of Baden-Württemberg (BW), Germany. Results: In all three groups patients were predominantly male (82%, 57%, and 68% for HCC, iCCA and cHCC-CCA groups, respectively). 48% of cHCC-CCA patients were diagnosed as stage IV cancers, which was more than for HCC (31%) but less compared to CCA (64%). Overall median survival of cHCC-CCA patients was worse compared to HCC (9-13 months vs. 15.5 months, p<0.001) and rather comparable to CCA (11.8 months). Conclusions: Our data demonstrated that cHCC-CCA tumors appear to have a distinct clinical course with worse overall survival compared to HCC. Thus, identification of these cancers by histopathology is essential in order to further characterize this tumor entity and to provide accurate treatment to these patients.

14 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SWSebastian Alfred Wohlfeil
Sebastian Alfred Wohlfeil
Jochen UtikalJochen Utikal
Jochen Utikal
CBChristiane Bauer-Auch
Christiane Bauer-Auch
ISIrina Surovtsova
Irina Surovtsova
TVTilo Vogel
Tilo Vogel
PMPhilipp Morakis
Philipp Morakis
Background: Sebaceous carcinoma (SC) is a rare malignant cutaneous malignancy. Methods: A multicenter retrospective study of 213 German patients with SC diagnosed between 2008 and 2024 was conducted. Data were extracted from the Baden-Württemberg Cancer Registry. Cases were separated into ocular and extraocular SC. Their demographic, clinical, and treatment-related characteristics were compared and influences on overall survival (OS) analyzed. Results: Most patients were elderly (median age: 79 years), with a male-to-female ratio of 2:1. Extraocular SC was more common in men, while ocular SC was more frequent in women. Most tumors were diagnosed at stage I, and microscopically controlled excision was the primary treatment modality (81.4%). Sentinel lymph node biopsy (2.3%), lymph node dissection (1.9%) and systemic therapy (1.4%) were only documented in a minority of cases. Survival analysis (median follow-up 3.2 years) revealed a median OS of 61.4 months in the entire cohort. No significant survival difference was observed between ocular and extraocular SC (64.8 vs. 53.7 months; p = 0.490), and multivariable analysis confirmed no prognostic impact of tumor localization (HR 1.4, 95% CI 0.85–2.4). Age was the only independent predictor of outcome, with strongly increased risk in patients aged 70–79 years (HR 4.4, 95% CI 1.01–19.2) and ≥80 years (HR 16.1, 95% CI 3.91–66.1). Prior malignancies, including MTS-like tumors and hematological neoplasms, were not independently associated with overall survival. Conclusions: In this multicenter cohort, sebaceous carcinoma showed no survival difference between ocular and extraocular disease, with age emerging as the main independent prognostic factor. Prior malignancies and tumor characteristics, including histologic grade, were not independently associated with outcome. Microscopically controlled excision appears to be an effective treatment option.

27 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ISIrina Surovtsova
Irina Surovtsova
WEWilfried Ernst Erich Eberhardt
Wilfried Ernst Erich Eberhardt
DMDorothea Elisabeth Meschke
Dorothea Elisabeth Meschke
PMPhilipp Morakis
Philipp Morakis
Background: Checkpoint inhibitors (CPIs) improve the survival in advanced NSCLC and ES-SCLC, but reproducibility of randomized trial results in routine practice remains unclear. Target trial emulation enables approximation of randomized trial designs using observational data while reducing common biases. Methods: Using the Baden-Württemberg Cancer Registry, we emulated four pivotal trials: KEYNOTE-189 (eKN189), KEYNOTE-407 (eKN407), IMpower133 (eIMP133), and PACIFIC (ePACIFIC). The eligibility criteria, treatment strategies, and outcomes were aligned with the original trials as closely as possible within registry constraints. Time-zero was defined as the treatment initiation for systemic therapy cohorts (eKN189, eKN407, eIMP133) and as completion of chemoradiotherapy for ePACIFIC. The treatment groups were balanced using propensity-score-based inverse probability weighting. The outcomes included the overall survival (OS) and the objective response rate (ORR). Results: A total of 4015 patients were included (eKN189: 1762; eKN407: 467; eIMP133: 1190; ePACIFIC: 595). After weighting, the baseline covariates were well balanced. ICI-based regimens were associated with an improved survival: eKN189: HR—0.59 (95% CI: 0.52–0.66), 5-year OS—22.7% vs. 4.7%; eKN407: HR—0.69 (95% CI: 0.54–0.89), 5-year OS—11.8% vs. 6.6%; eIMP133: HR—0.7 (95% CI: 0.62–0.79), 5-year OS—12.8% vs. 5.3%; ePACIFIC: HR—0.51 (95% CI: 0.39–0.66), 5-year OS—47.3% vs. 23.4%. The OS curves demonstrated long-term plateaus across CPI-containing arms. The ORRs were consistently higher with CPI-containing regimens (eKN189: 41.6% vs. 29.6%; eKN407: 44.8% vs. 31.5%; eIMP133: 51.7% vs. 43.1%; ePACIFIC: 56.6% vs. 47.1%). Conclusions: This registry-based target trial emulation reproduced the survival patterns observed in four landmark lung cancer RCTs within trial-like real-world populations, supporting the external validity of pivotal immunotherapy trials while reinforcing the role of high-quality registries as a powerful complement to randomized trials in oncology.

6 November 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
APAndré Pfob
André Pfob
ISIrina Surovtsova
Irina Surovtsova
DKDaria B. Kokh
Daria B. Kokh
KSKatharina Smetanay
Katharina Smetanay
ASAndreas Schneeweiss
Andreas Schneeweiss
PMPhilipp Morakis
Philipp Morakis
We aimed to evaluate the use of bevacizumab in patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian and fallopian tube cancer undergoing primary debulking surgery, using real-world data from a German cancer registry. Patients with a first diagnosis of International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian or fallopian tube cancer diagnosed between 2009 and 2023 were identified from the Baden-Wuerttemberg Cancer Registry. Outcomes of patients receiving carboplatin and paclitaxel±bevacizumab were compared. Progression-free survival and overall survival were analyzed using multivariable Cox regression, adjusting for age, grade, stage, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor use, and surgical outcome. Sub-group analyses were performed according to residual disease, categorized as optimal debulking or sub-optimal debulking, and by PARP inhibitor use. Among 1469 patients (median follow-up 37.8 months), 969 (66%) had stage IIIB/C and 500 (34%) stage IV disease. Optimal debulking was achieved in 842 patients (57.3%). Overall, 54.5% received carboplatin+paclitaxel+bevacizumab: 54.2% with optimal and 52.3% with sub-optimal debulking. Bevacizumab improved progression-free survival (hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.65 to 0.93) and overall survival (HR 0.79, 95% CI 0.65 to 0.96) in suboptimal debulking, but not in optimal debulking (overall survival HR 0.88, 95% CI 0.72 to 1.1; progression-free survival HR 0.91, 95% CI 0.76 to 1.1). Sub-group analyses suggested PARP inhibitor therapy may obscure or outweigh bevacizumab's impact. Bevacizumab is frequently used in primary debulking surgery for advanced ovarian cancer. Survival benefits are mainly observed in patients with residual disease, while PARP inhibitor therapy may influence these effects. Real-world evidence complements clinical trials and informs treatment decisions.

18 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CHCorinne Hübers
Corinne Hübers
Jochen UtikalJochen Utikal
Jochen Utikal
SWSebastian Alfred Wohlfeil
Sebastian Alfred Wohlfeil
ISIrina Surovtsova
Irina Surovtsova
COCigdem Oswald
Cigdem Oswald
PMPhilipp Morakis
Philipp Morakis
Background: Pleomorphic dermal sarcoma (PDS) is a rare, cutaneous sarcoma predominantly affecting sun-exposed skin in elderly patients. Surgical excision remains the mainstay of treatment, but evidence on optimal management and long-term outcomes is limited. Methods: We retrospectively analyzed 1069 patients diagnosed with PDS between 2009 and 2025 using data from the Baden-Württemberg Cancer Registry, Germany. Patient characteristics, surgical management, resection status, and preceding malignancies were evaluated. Temporal surgical trends were assessed using multivariable logistic regression. Overall survival (OS) was analyzed using Kaplan–Meier estimates and multivariable Cox regression. Results: Median age was 82 years, and 83.7% of patients were male. The hair-bearing scalp was the most frequent tumor site (55.0%). Among 449 patients with documented surgical procedures, 82.0% underwent micrographically controlled surgery (MGC), with increasing use over time (adjusted OR per year, 1.19; 95% CI, 1.11–1.29). R0-resections were comparable between MGC and conventional resection (75.7% vs. 71.6%). Among 679 patients evaluated for preceding malignancies, 39.7% had a documented cancer history, including 4.4% with hematologic malignancies. Among 723 patients with reliable follow-up, median OS was 72.4 months (95% CI, 61.3–82.1). Mortality was strongly associated with age, but not anatomical tumor site. Surgical approach was not significantly associated with OS after adjustment (MGC vs. conventional resection: HR, 1.49; 95% CI, 0.95–2.3; p = 0.083). Conclusions: This large registry-based study provides real-world evidence on PDS management and prognosis. The increasing adoption of MGC supports its growing role in clinical practice, while the high frequency of preceding malignancies highlights the complex oncological history of patients with PDS.